Phase I/II single-arm, open-label clinical trial assessing NTI164 in paediatric patients spastic diplegia cerebral palsy (CP)
Latest Information Update: 14 Oct 2024
Price :
$35 *
At a glance
- Drugs NTI 164 (Primary)
- Indications Cerebral palsy
- Focus Adverse reactions; Therapeutic Use
- 14 Oct 2024 New trial record